Working… Menu

AXER-204 in Participants With Chronic Spinal Cord Injury (RESET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03989440
Recruitment Status : Recruiting
First Posted : June 18, 2019
Last Update Posted : January 20, 2021
Information provided by (Responsible Party):
ReNetX Bio, Inc.

Brief Summary:
This two-part trial will assess the safety, tolerability, pharmacokinetics, and efficacy of AXER-204 administered by lumbar puncture and slow bolus infusion. Part 1 will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses of AXER-204. Part 2 will evaluate the safety, tolerability, pharmacokinetics, and efficacy of repeated doses AXER-204 in comparison to placebo.

Condition or disease Intervention/treatment Phase
Chronic Spinal Cord Injury Drug: AXER-204 Drug: Placebo Phase 1 Phase 2

Detailed Description:

AXER-204 is a human fusion protein that acts as a soluble decoy/trap for the myelin-associated inhibitors of axonal growth known as Nogo-A, MAG, and OMgp. AXER-204 and a surrogate protein used in early preclinical studies have been found to promote axon growth and recovery of function in animal models of spinal cord injury.

Part 1 of the trial is a multicenter, open-label, single ascending dose study in participants with chronic cervical spinal cord injury. Four cohorts of 6 participants each are planned, with participants within each cohort expected to receive the same dose of AXER-204.

Part 2 is a multicenter, randomized, double-blind, placebo-controlled, repeat dose study in chronic cervical spinal cord injury participants. Approximately 32 participants will be randomized (ratio 1:1) to receive repeated doses of AXER-204 or placebo (a phosphate buffered saline formulation). The dose level and dose frequency will be dependent upon outcomes from Part 1.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part 1 is open-label single-ascending dose. Part 2 is double-blind, placebo-controlled, repeat dose.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Part 1 - None; Part 2 - Quadruple
Primary Purpose: Treatment
Official Title: A Multicenter, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AXER-204 in Subjects With Chronic Spinal Cord Injury
Actual Study Start Date : July 16, 2019
Estimated Primary Completion Date : June 2022
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AXER-204
Part 1 - Single ascending doses; Part 2 - Repeated dose
Drug: AXER-204
human NoGo Trap fusion protein
Other Names:
  • human NoGo Trap
  • human Nogo Receptor decoy

Placebo Comparator: Placebo
Part 2 only - Repeated dose
Drug: Placebo
Phosphate buffered saline formulation

Primary Outcome Measures :
  1. Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Day 1 Post-dose to 28-days after last dose ]
    An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. An SAE is any untoward medical occurrence that at any dose results in death, is a life-threatening event, requires inpatient hospitalization or prolongation of existing hospitalization, results in a significant disability/incapacity or congenital anomaly, or is a medically important event.

  2. Area Under the Concentration-Time Curve From Time 0 to Time of the Last Measurable Concentration (AUClast) of AXER-204 [ Time Frame: Day 1 pre-dose up to Day 29 ]
    AXER-204 will be measured in cerebrospinal fluid (CSF) and in serum

Secondary Outcome Measures :
  1. Change in International Standards for Neurological Classification of SCI (ISNCSCI) Upper Extremity Motor Score (UEMS) [ Time Frame: Baseline to Day 169 and Day 253 ]
    The ISNCSCI scale includes a Motor and Sensory examination for each side of the body (left/right). The Sensory examination involves 'light touch' and 'pinprick' for each dermatome (28) on both sides of the body (total 56). A score of 0, 1 or 2 can be given to each dermatome resulting in a total max. of 112 points. The Motor level is determined by examining the muscle function within each of the 10 myotomes on each side of the body (20 myotomes in total). A score ranging from 1 to 5 can be given to each myotome tested resulting in a maximum score of 100 (50 for upper extremity and 50 for lower extremity). Higher values indicate better function with the maximum scores corresponding to normal function.

  2. Change in Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP) scores [ Time Frame: Baseline to Day 169 and Day 253 ]
    The GRASSP is a clinical impairment measure for the upper limb for use after tetraplegia. The measure includes domains which are important in describing hand function: Strength with scores from 0-50 for each side, Sensory testing with scores ranging from 0-12 for each hand, Prehension ability with scores 0-12 for each hand, and Prehension performance with scores from 0-30 for each hand. Higher subscores indicate better function.

  3. Change in version III of the Spinal Cord Independence Measure (SCIM III) self-care and mobility domain scores [ Time Frame: Baseline to Day 169 and Day 253 ]
    The SCIM III is a questionnaire that assesses activities of daily living (ADL) regarding self-care, mobility, respiration, and sphincter management. The self-care and mobility domains have scores ranging from 0-20 and 0-40 respectively. Higher scores correspond to better ability to carry out ADL.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  1. Traumatic spinal cord injury that occurred ≥ 1 year ago
  2. Cervical spinal cord injury with serious neurologic deficit as evidenced by 1) bilateral ISNCSCI UEMS between 4 and 36 points inclusive, and 2) bilateral GRASSP Prehension Ability score between 4 and 17 points inclusive
  3. Confirmation by MRI of the following:

    1. Chronic SCI (persistent spinal cord lesion)
    2. For AIS grade of A without sensory or motor zone of partial preservation extending at least two levels caudal to the level of injury, no apparent transection of the cord
    3. CSF space spanning the lesion

Key Exclusion Criteria:

  1. Penetrating injury to the cord or spinal cord trauma caused by ballistic injury including gunshot that did not penetrate the spinal cord
  2. History of stroke, cerebrovascular injury, or elevated intracranial pressure
  3. Contraindications for lumbar puncture
  4. Requiring mechanical ventilatory assistance of any type
  5. Body mass index (BMI) ≥ 35 kg/m2 or body weight <50 kg
  6. History of life threatening allergic or immune-mediated reaction to vaccines, or biologic drugs, at any time or any life threatening allergic or immune-mediated reaction within the past 12 months
  7. Subjects fitted with an implanted pump or port for delivery of therapeutics to the CSF
  8. Uncontrolled medical condition including but not limited to cardiovascular disease, sleep apnea, obstructive lung disease, severe neuropathic or severe chronic pain, severe autonomic dysreflexia
  9. Participation in any other investigational drug or device trial within 30 days or within 5 half-lives of the investigational drug or any past participation in a SCI cellular therapy trial.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03989440

Layout table for location contacts
Contact: Gilbert Block, Chief Medical Officer, MD, PhD 1-203-208-8925

Layout table for location information
United States, California
Keck Medicine of USC Recruiting
Los Angeles, California, United States, 90033
Contact: Sandra Oviedo   
Principal Investigator: Charles Liu, MD, PhD         
United States, Georgia
Shepherd Center Recruiting
Atlanta, Georgia, United States, 30309
Contact: Casey Kandilakis, PT,DPT,NCS   
Principal Investigator: Donald Leslie, MD         
United States, Illinois
Shirley Ryan AbilityLab Recruiting
Chicago, Illinois, United States, 60611
Contact: Connie Casale    312-238-1522   
Principal Investigator: David Chen, MD         
United States, Massachusetts
Spaulding Rehabilitation Not yet recruiting
Boston, Massachusetts, United States, 02129
Contact: Jenny Min    617-952-6173   
Principal Investigator: Ross Zafonte, DO         
Sub-Investigator: Chloe Slocum, MD, MPH         
United States, Ohio
The Ohio State University Wexner Medical Center Recruiting
Columbus, Ohio, United States, 43210
Contact: Amy Bartlett, BA, CCRC    614-366-9050   
Principal Investigator: Jan Schwab, MD, PhD         
United States, Pennsylvania
Thomas Jefferson University Recruiting
Philadelphia, Pennsylvania, United States, 19107
Contact: Marilyn Owens, RN, BSN         
Principal Investigator: Ralph Marino, MD         
Sponsors and Collaborators
ReNetX Bio, Inc.
Layout table for investigator information
Study Director: George Maynard, PhD ReNetX Bio
Layout table for additonal information
Responsible Party: ReNetX Bio, Inc. Identifier: NCT03989440    
Other Study ID Numbers: RNX-AX204-101
First Posted: June 18, 2019    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ReNetX Bio, Inc.:
myelin-associated inhibitor
Nogo Receptor
Additional relevant MeSH terms:
Layout table for MeSH terms
Spinal Cord Injuries
Wounds and Injuries
Spinal Cord Diseases
Central Nervous System Diseases
Nervous System Diseases
Trauma, Nervous System